Early Deals Shape Startups More Than Technology

Why Early Deals Shape Your Startup More Than Your Technology

The most dangerous early traction is the kind that looks like progress but can’t scale.

The Illusion of Early Traction

Early-stage founders often celebrate their first deals as proof of progress.

A pilot signed. A partner engaged. A customer willing to experiment.

But not all deals are created equal. Some accelerate growth. While others quietly constrain it.

The difference is rarely visible in the moment but it becomes obvious later, when scaling proves far harder than expected.

According to a 2022 study by Deloitte, more than 70% of pilot programs fail to convert into full-scale deployment with commercial misalignment, not technical performance, as a primary driver.

Early traction, in other words, is often a false positive.

When Early Deals Point You in the Wrong Direction

The risk with early deals is that they can limit the future by pointing the company toward the wrong market entirely. We have an excellent example of this with the company HeartFlow.

In its early stages, HeartFlow pursued research-use-only (RUO) contracts with academic medical centers. These deals generated data, validation, and early credibility which is the kind of traction founders are encouraged to pursue.

But structurally, these deals didn’t scale. In healthcare, adoption is driven by clinical validation, but the more important driver is reimbursement.

The team recognized that continuing to pursue small research contracts would trap them in a cycle of:

• fragmented pilots

• non-scalable revenue

• limited market adoption

By pursuing this strategy instead of building a business they were just accumulating activity that trapped them in an endless cycle of difficult to scale revenue.

To break this cycle, HeartFlow made and major pivot and shifted its entire strategy toward:

• regulatory approval

• health-economic validation

• reimbursement pathways through CPT codes and insurers

The Outcome: This pivot unlocked the market. HeartFlow scaled from small research engagements to adoption across 1,000+ healthcare institutions globally, with a commercial model aligned to how healthcare is actually funded. HeartFlow didn’t need to change the technology but the commercial pathway.

This Pattern Shows Up Everywhere

Even in consumer technology, the signal is the same. Pinterest began as a mobile shopping app called Tote. Early traction looked promising but users were saving instead of completing transactions. Instead of forcing a business model that didn’t fit user behavior, the company pivoted to a curation and discovery platform. That shift unlocked scale because it aligned with how the market actually behaved and not how the initial “deal” was structured.

Deals Are Strategy in Disguise

Early agreements don’t just generate revenue.

They define:

• Pricing power → what the market expects to pay

• Positioning → vendor vs partner vs infrastructure

• Expansion pathways → how easily you scale across customers

• Capital efficiency → how hard it is to grow

From a capital markets perspective, this matters deeply.

In its 2023 report, “The State of AI”, McKinsey & Company found that while adoption of advanced technologies is widespread, only a minority of companies capture meaningful financial impact largely due to challenges in scaling commercial deployment.

Similarly, Boston Consulting Group noted in its 2019 report “The Most Innovative Companies” that companies failing to align business models early face longer time-to-scale and higher capital intensity, even when their technology is strong.

Investors don’t just evaluate revenue. They evaluate: how that revenue was constructed and whether it can scale.

A Practitioner’s Observation: The Best Deals Do Three Things

Across sectors, the most effective early-stage deals consistently share three characteristics:

1. Preserve Optionality: avoid exclusivity or narrow constraints that limit future partnerships.

2. Align Incentives: structure agreements where both parties benefit from scale beyond initial engagement.

3. Create Repeatability: design deals that can be replicated across customers without reinvention.

What This Looks Like in Practice

Consider a deep-tech materials startup working with a global manufacturer. Let’s contrast the typical approach to a structured approach focused on scale:

Typical Approach:

• one-off pilot

• bespoke pricing

• no defined expansion pathway

Outcome:

• technical validation

• no scalable commercial momentum

Structured Approach

• pilot tied to multi-site deployment triggers

• pricing framework introduced early, even if flexible

• defined pathway to preferred supplier status

• alignment with procurement and operations teams upfront

Outcome:

• validation + commercial clarity

• faster expansion

• credible signals for investors

Same partner with a completely different trajectory because of the structured approach.

Closing Thoughts:

Founders often believe their technology defines their trajectory. In reality, their early deals do.

The right agreements create leverage and the wrong ones create constraints. And by the time the difference is visible in stalled growth, margin pressure, or investor skepticism then it is often too late to unwind the decisions that caused it.

If you’re structuring early partnerships or pilot agreements and want to ensure they support long-term scale not limit it then we welcome the conversation.